Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1997018838) THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/018838 International Application No.: PCT/US1996/018807
Publication Date: 29.05.1997 International Filing Date: 21.11.1996
Chapter 2 Demand Filed: 10.06.1997
IPC:
A61K 38/00 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
ATHENA NEUROSCIENCES, INC. [US/US]; 800 Gateway Boulevard South San Francisco, CA 94080, US (AllExceptUS)
BENDIG, Mary, M. [US/GB]; GB (UsOnly)
LEGER, Olivier, J. [FR/GB]; GB (UsOnly)
SALDANHA, Jose [GB/GB]; GB (UsOnly)
JONES, S., Tarran [GB/GB]; GB (UsOnly)
YEDNOCK, Ted, A. [US/US]; US (UsOnly)
Inventors:
BENDIG, Mary, M.; GB
LEGER, Olivier, J.; GB
SALDANHA, Jose; GB
JONES, S., Tarran; GB
YEDNOCK, Ted, A.; US
Agent:
LEIBESCHUETZ, Joe ; Townsend and Townsend and Crew LLP Two Embarcadero Center 8th floor San Francisco, CA 94111-3834, US
Priority Data:
08/561,52121.11.1995US
Title (EN) THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
(FR) UTILISATIONS THERAPEUTIQUES D'ANTICORPS HUMANISES CONTRE L'ALPHA-4 INTEGRINE
Abstract:
(EN) The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.
(FR) Cette invention concerne des procédés de traitement dans lesquels on utilise des immunoglobulines qui se lient spécifiquement à l'alpha-4 intégrine. Ces procédés sont utiles pour traiter l'asthme, l'athérosclérose, la dégénérescence liée au SIDA, le diabète, la maladie intestinale inflammatoire, la polyarthrite rhumatoïde, le rejet de transplant, la maladie du greffon contre l'hôte, la métastase de tumeur, la néphrite, la dermatite atopique, le psoriasis, l'ischémie du myocarde et les lésions aiguës du poumon à médiation leucocytaire.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0921815JP2000500501 CA2237808AU1997012736